Immediate Impact
64 standout
Citing Papers
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Targeting immunogenic cell stress and death for cancer therapy
2024 Standout
Works of Paul Mésange being referenced
Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
2018
Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Paul Mésange | 65 | 89 | 45 | 88 | 12 | 219 | |
| Florian Klinglmüller | 74 | 116 | 54 | 73 | 12 | 285 | |
| Ji‐Hye Oh | 88 | 84 | 70 | 55 | 13 | 204 | |
| Helle Wulf-Johansson | 22 | 84 | 48 | 97 | 11 | 256 | |
| Yibo Cai | 154 | 73 | 33 | 54 | 19 | 276 | |
| T. W. Kim | 89 | 64 | 19 | 158 | 14 | 263 | |
| Rongfeng Song | 47 | 109 | 71 | 57 | 16 | 219 | |
| Elvira Stacher‐Priehse | 29 | 100 | 71 | 101 | 14 | 214 | |
| Laura Mastrangelo | 96 | 95 | 63 | 69 | 10 | 289 | |
| Aditya S. Shirali | 45 | 172 | 65 | 49 | 9 | 282 | |
| Zan Lv | 63 | 153 | 46 | 46 | 10 | 297 |
All Works
Loading papers...